Mangold inleder bevakning av medicinteknikbolaget PolarCool.
EE headwinds from programme end-of-life and automotive market Mix effects and major FX revaluations ...
Vi inleder bevakning på Xoma, en svensk teknikleverantör som utvecklar landbaserade system för algod...
Redeye provides its thoughts on the rights issue.
The recent acquisition of Norwegian point-of-care diagnostics platform SpinChip by bioMérieux for EU...
Redeye expects Smart Eye’s Q4 report, due 18 February, to show a 4% y/y sales growth and an EBITDA i...
Redeye is very pleased to see that OXE Marine has received another major order from the US Governmen...
Strong Q4 with a beat on all headline items... ...adds more fuel to '25e growth: guidance remains to...
Vaisala’s Q4 turned out to be very strong as the operating result was higher than the company previo...
Duell delivered slightly better figures than we had expected for the seasonally quiet Q1 of its fisc...
22% ARR growth and a solid 11% adj. EBITDA beat '25 guidance raised; adj.
Redeye briefly comments on MedCap releasing preliminary Q4 2024 figures, significantly undershooting...
Redeye is impressed by the strong preliminary Q4 results, demonstrating an EBIT breakeven several qu...
Redeye comments on the recent news regarding Integrum’s partnership with Intelerad.
Redeye comments on the positive interaction with the FDA about ongoing CMC work for the planned phas...
Duell reported Q1 net sales at EUR 28.3m, just surpassing our forecast of EUR 27.
Redeye takes a positive stance on the news that Sivers is raising SEK108m through a directed share i...
Safello pre-announced key metrics for its Q4 2024 report due 21/02/2025.
Redeye endorses today’s news that Cephagenix has secured funding of up to EUR9m and gives an initial...
Redeye makes a brief comment on today’s news of the CEO replacement.